Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified HLH-94 protocol with etoposide plus prednisolone for severe COVID-19
jRCT2021210012Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide and prednisolone in coronavirus disease 2019 (COVID-19), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in pulmonary status. Started Jun 2021; status: completed.
02
Drugs
etoposideprednisolone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2021210012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210012.